Literature DB >> 16651629

Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes.

Monika Kasprzycka1, Miroslaw Majewski, Zhi-Jong Wang, Andrzej Ptasznik, Maria Wysocka, Qian Zhang, Michal Marzec, Phyllis Gimotty, Mark R Crompton, Mariusz A Wasik.   

Abstract

Tyrosine kinases play a fundamental role in cell proliferation, survival, adhesion, and motility and have also been shown to mediate malignant cell transformation. Here we describe constitutive expression of the protein tyrosine kinase Brk in a large proportion of cutaneous T-cell lymphomas and other transformed T- and B-cell populations. The kinase is expressed in the nuclear localization and activated state. Brk expression was also induced in normal T cells on their activation. Introduced expression of the Brk gene resulted in markedly diminished cytokine and growth factor dependence of transfected BaF3 lymphocytes in regard to their in vitro proliferation and survival. Brk also conferred in vivo oncogenicity on the BaF3 cells. siRNA-mediated inhibition of the endogenous Brk in malignant T cells diminished their growth and survival capacity. These findings document inducible expression of Brk in normal T lymphocytes and persistent expression of the activated kinase in malignant T and B cells. Furthermore, our results indicate that Brk may play a key role in lymphomagenesis, hence identifying the kinase as a potential therapeutic target in lymphomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651629      PMCID: PMC1606578          DOI: 10.2353/ajpath.2006.050521

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  29 in total

1.  Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.

Authors:  Andrzej Ptasznik; Yuji Nakata; Anna Kalota; Stephen G Emerson; Alan M Gewirtz
Journal:  Nat Med       Date:  2004-10-24       Impact factor: 53.440

2.  BRK/Sik expression in the gastrointestinal tract and in colon tumors.

Authors:  X Llor; M S Serfas; W Bie; V Vasioukhin; M Polonskaia; J Derry; C M Abbott; A L Tyner
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

3.  Simultaneous over-expression of the Her2/neu and PTK6 tyrosine kinases in archival invasive ductal breast carcinomas.

Authors:  Martina Born; Leticia Quintanilla-Fend; Herbert Braselmann; Uli Reich; Manfred Richter; Peter Hutzler; Michaela Aubele
Journal:  J Pathol       Date:  2005-04       Impact factor: 7.996

4.  A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation.

Authors:  V Vasioukhin; A L Tyner
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

5.  Regulated association of protein kinase B/Akt with breast tumor kinase.

Authors:  Ping Zhang; Julie Hanson Ostrander; Emily J Faivre; Abby Olsen; Daniel Fitzsimmons; Carol A Lange
Journal:  J Biol Chem       Date:  2004-11-10       Impact factor: 5.157

6.  The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders.

Authors:  M Majewski; M Korecka; P Kossev; S Li; J Goldman; J Moore; L E Silberstein; P C Nowell; W Schuler; L M Shaw; M A Wasik
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-11       Impact factor: 11.205

7.  BRK tyrosine kinase expression in a high proportion of human breast carcinomas.

Authors:  K T Barker; L E Jackson; M R Crompton
Journal:  Oncogene       Date:  1997-08-14       Impact factor: 9.867

8.  Brk, a breast tumor-derived non-receptor protein-tyrosine kinase, sensitizes mammary epithelial cells to epidermal growth factor.

Authors:  T Kamalati; H E Jolin; P J Mitchell; K T Barker; L E Jackson; C J Dean; M J Page; B A Gusterson; M R Crompton
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

9.  Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.

Authors:  Hsin-Yi Chen; Che-Hung Shen; Yuh-Tyng Tsai; Feng-Chi Lin; Yuan-Ping Huang; Ruey-Hwa Chen
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

10.  The nuclear tyrosine kinase BRK/Sik phosphorylates and inhibits the RNA-binding activities of the Sam68-like mammalian proteins SLM-1 and SLM-2.

Authors:  Andrea Haegebarth; Darien Heap; Wenjun Bie; Jason J Derry; Stéphane Richard; Angela L Tyner
Journal:  J Biol Chem       Date:  2004-10-07       Impact factor: 5.157

View more
  19 in total

1.  Kinase-Dependent and -Independent Roles for PTK6 in Colon Cancer.

Authors:  Priya S Mathur; Jessica J Gierut; Grace Guzman; Hui Xie; Rosa M Xicola; Xavier Llor; Michael I Chastkofsky; Ansu O Perekatt; Angela L Tyner
Journal:  Mol Cancer Res       Date:  2016-03-16       Impact factor: 5.852

2.  Identification of beta-catenin as a target of the intracellular tyrosine kinase PTK6.

Authors:  Helena L Palka-Hamblin; Jessica J Gierut; Wenjun Bie; Patrick M Brauer; Yu Zheng; John M Asara; Angela L Tyner
Journal:  J Cell Sci       Date:  2009-12-21       Impact factor: 5.285

Review 3.  Brk/PTK6 signaling in normal and cancer cell models.

Authors:  Julie H Ostrander; Andrea R Daniel; Carol A Lange
Journal:  Curr Opin Pharmacol       Date:  2010-09-09       Impact factor: 5.547

4.  Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.

Authors:  You-Fang Chen; Gang Ma; Xun Cao; Zhi-Liang Huang; Mu-Sheng Zeng; Zhe-Sheng Wen
Journal:  Med Oncol       Date:  2014-11-07       Impact factor: 3.064

5.  PTK6 inhibits down-regulation of EGF receptor through phosphorylation of ARAP1.

Authors:  Shin-Ae Kang; Eun-Saem Lee; Hye-Young Yoon; Paul A Randazzo; Seung-Taek Lee
Journal:  J Biol Chem       Date:  2010-06-16       Impact factor: 5.157

Review 6.  Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.

Authors:  Patrick M Brauer; Angela L Tyner
Journal:  Biochim Biophys Acta       Date:  2010-02-26

Review 7.  Targeting protein tyrosine kinase 6 in cancer.

Authors:  Milica B Gilic; Angela L Tyner
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-09-18       Impact factor: 10.680

8.  Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.

Authors:  Nancy E Castro; Carol A Lange
Journal:  Breast Cancer Res       Date:  2010-08-05       Impact factor: 6.466

9.  The alternative splice variant of protein tyrosine kinase 6 negatively regulates growth and enhances PTK6-mediated inhibition of β-catenin.

Authors:  Patrick M Brauer; Yu Zheng; Mark D Evans; Carmen Dominguez-Brauer; Donna M Peehl; Angela L Tyner
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

10.  Induction of protein tyrosine kinase 6 in mouse intestinal crypt epithelial cells promotes DNA damage-induced apoptosis.

Authors:  Andrea Haegebarth; Ansu O Perekatt; Wenjun Bie; Jessica J Gierut; Angela L Tyner
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.